Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819295 | 0.98 | ELANE (0.44) | ELANEPDE4BPDE4DCYP2C9CYP3A4 | |
| SCHEMBL19523439 | 0.89 | ELANE (0.41) | ELANE | |
| SCHEMBL17831248 | 0.89 | USP14 (0.38) | ELANEPDE4BPDE4D | |
| SCHEMBL19523443 | 0.88 | ELANE (0.42) | ELANEPDE4BPDE4D | |
| SCHEMBL17819344 | 0.87 | ELANE (0.57) | ELANEPDE4BPDE4DCYP2C9CYP3A4 | |
| SCHEMBL17819337 | 0.87 | ELANE (0.46) | ELANEPDE4BPDE4DCYP2C9CYP3A4 | |
| SCHEMBL19639827 | 0.87 | ELANE (0.41) | ELANECYP2C9CYP3A4 | |
| SCHEMBL17964358 | 0.86 | ELANE (0.47) | ELANECYP2C9CYP3A4 | |
| SCHEMBL17819348 | 0.86 | ELANE (0.57) | ELANEPDE4BPDE4DCYP2C9CYP3A4 | |
| SCHEMBL21859873 | 0.85 | ELANE (0.56) | ELANEPDE4BPDE4DCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | claimed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | claimed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | claimed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| WO-2016096638-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | ELANE 1/4885PDE4B 1169/4885PDE4D 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.